Pharmaceuticals
Neurodegenerative Diseases Drugs Market

Neurodegenerative Diseases Drugs Market Size, Share, Trends, Growth, and Forecasts for 2025 - 2032

Neurodegenerative Diseases Drugs Market by Drug Class (Immunomodulator, Interferons), by Disease Indication (Multiple Sclerosis, Parkinson’s Disease), by Route of Administration (Oral, Injection), by End-use, and Regional Analysis for 2025 - 2032

ID: PMRREP35538

July 2025

200 Pages

Author : Abhijeet Surwase

Healthcare

Neurodegenerative Diseases Drugs Market Size and Trends

The neurodegenerative diseases drugs market size is likely to be valued at US$ 58.4 Bn in 2025 and is estimated to reach US$ 85.0 Bn in 2032, growing at a CAGR of 5.5% during the forecast period 2025-2032. Breakthrough regulatory approvals, biomarker-based precision targeting, and rising demand for disease-modifying therapies have encouraged the development of drugs for neurodegenerative diseases. An aging population is pushing incidence rates across Alzheimer’s, Parkinson’s, and multiple sclerosis. Hence, pharmaceutical companies are adjusting their research and development priorities to capitalize on high-value biologics, immunomodulators, and regenerative platforms. Increasing investment, cross-border collaborations, and payer engagement are further positioning neurodegeneration as a key growth frontier in the global neurology market.

global-neurodegenerative-diseases-drugs-market-size-2025–2032

Key Industry Highlights:

Shift from symptomatic treatment to targeted immunomodulation and biologics is a leading market trend.
Rising healthcare expenditure and reimbursement frameworks for neurological care are anticipated to boost the market.
Development of therapies targeting non-motor symptoms in Parkinson’s is expected to create new growth avenues.
Immunomodulators are speculated to hold around 43.5% share in 2025 due to proven efficacy in halting inflammatory pathways central to various neuroinflammatory conditions.
Multiple sclerosis remains the dominant disease indication as consistent funding and patient advocacy bolster sustained development and early adoption of new drugs.
Development of a unique diagnostic infrastructure supporting early-stage treatment and drug eligibility is propelling growth across North America.

Global Market Attribute	Key Insights
Neurodegenerative Diseases Drugs Market Size (2025E)	US$ 58.4 Bn
Market Value Forecast (2032F)	US$ 85.0 Bn
Projected Growth (CAGR 2025 to 2032)	5.5%
Historical Market Growth (CAGR 2019 to 2024)	4.1%

Market Dynamics

Driver - Early Diagnosis Pushes Demand for Unique Treatments

Increasing emphasis on early diagnosis and intervention is accelerating the neurodegenerative diseases drugs market growth by expanding the eligible treatment population. The approval of lecanemab in the U.S., Japan, and certain European countries for early-stage Alzheimer’s disease has increased demand for early screening. It is prompting healthcare facilities to invest in PET imaging, CSF biomarker assays, and blood-based diagnostics. This shift has resulted in an increasing demand for drugs that target pathophysiological mechanisms before irreversible neuronal damage occurs.

Eli Lilly’s donanemab showed a 35% slowing of cognitive decline in early-stage Alzheimer’s in its TRAILBLAZER-ALZ 2 trial. This demonstrated that efficacy is powerful when administered during preclinical or mild cognitive impairment phases. Hence, payers and healthcare institutions are becoming more willing to reimburse such therapies when supported by biomarker-confirmed diagnoses. This is directly pushing pharmaceutical companies to focus their pipelines on prodromal-stage treatments.

Restraint - Reimbursement Bias and Diagnostic Gaps Stall Rollout of New Drugs

The historical reliance on symptomatic treatments in neurodegenerative diseases has hampered the adoption of new and potentially disease-modifying drugs. Most existing therapies such as donepezil for Alzheimer’s or levodopa for Parkinson’s, provide temporary relief without altering the disease pattern. This treatment model has created skepticism among clinicians and patients regarding the long-term value of the latest drugs. The tendency to manage symptoms rather than intervene early in disease biology has also limited investment in diagnostic infrastructure necessary for disease-modifying therapies.

Various such treatments require biomarker-confirmed diagnoses. However, a 2024 survey by the Alzheimer’s Association found that fewer than 30% of neurologists in the U.S. routinely order amyloid PET scans or CSF tests. It is mainly due to cost, limited access, and uncertainty over actionable outcomes. Hence, even when disease-modifying drugs are approved, real-world implementation falters in the absence of supporting systems. In addition, reimbursement frameworks in several regions still favor low-cost and established symptomatic drugs.

Opportunity - Stem Cell Developments Push New Drug Pipelines

The exploration of stem cell therapy as a regenerative approach in neurodegenerative diseases is creating new opportunities for drug developers. It is gradually shifting the treatment focus from symptomatic relief to actual neuronal restoration. Stem cell-based interventions aim to repopulate damaged neural circuits and offer long-term disease modification. This is prompting pharmaceutical and biotech companies to co-develop drugs that improve stem cell efficacy. At the same time, they are focusing on creating combination regimens involving immunomodulators or small molecules to refine the host environment for cell engraftment.

Recent trials emphasize this potential. In 2024, for example, BlueRock Therapeutics, a Bayer subsidiary, initiated Phase 2 trials of its dopamine-producing iPSC-derived cell therapy for Parkinson’s disease in the U.S. and Canada. Early results from its Phase 1 trial showed not only safety but also signs of improved motor function in participants. Such results have spurred interest in developing adjunctive drugs that reduce neuroinflammation and oxidative stress.

Get Your CustomizationGet Your Customization

Category-wise Analysis

Drug Class Insights

In terms of drug class, the market is segregated into immunomodulator, interferons, decarboxylase inhibitors, dopamine agonists, and others. Out of these, immunomodulators are poised to hold nearly 43.5% of the neurodegenerative diseases drugs market share in 2025 with their ability to target core disease mechanisms involving neuroinflammation and immune dysregulation. In multiple sclerosis, which has a well-defined autoimmune basis, immunomodulators are the backbone of therapy. The class’s appeal is also supported by regulatory precedent and biomarker-enabled patient stratification.

Dopamine agonists are gaining momentum in the treatment of Parkinson’s disease. This is attributed to their expanding therapeutic utility, improved delivery mechanisms, and reduced long-term complications compared to conventional levodopa-based regimens. While levodopa remains the gold standard for symptomatic relief, long-term use is associated with motor fluctuations and dyskinesias. Dopamine agonists, including pramipexole, ropinirole, and rotigotine, are being used in early-stage Parkinson’s to delay levodopa initiation.

Disease Indication Insights

Based on disease indication, the market is divided into multiple sclerosis, Parkinson’s disease, Alzheimer's disease, Spinal Muscular Atrophy (SMA), and others. Among these, multiple sclerosis is projected to hold around 62.6% of share in 2025 owing to its well-characterized autoimmune pathology, accessible biomarkers, and the presence of clear clinical endpoints. It is characterized by demyelination and neuroinflammation, making it responsive to immunomodulatory therapies. This has resulted in the approval of more than 20 Disease-Modifying Therapies (DMTs) globally.

Alzheimer’s disease stands out as a key disease indication backed by its immense patient burden, political visibility, and the commercial incentives linked to disease-modifying breakthroughs. According to Alzheimer’s Association, more than 7 Mn individuals in the U.S. are living with the disease and by 2050, the number is estimated to surge to approximately 13 Mn. This epidemiological pressure has pushed it to the forefront of both public health agendas and pharmaceutical pipelines.

global-neurodegenerative-diseases-drugs-market-outlook-by-drug-class-2025–2032

Regional Insights

North America Neurodegenerative Diseases Drugs Market Trends

In 2025, North America is predicted to account for approximately 51.8% of share due to rising public funding, accelerated regulatory pathways, and high unmet clinical requirement. The U.S. neurodegenerative diseases drugs market is estimated to witness steady growth with the Food and Drug Administration’s (FDA) approval of Eisai and Biogen’s Leqembi. It marked a key milestone as the first fully approved anti-amyloid drug for early-stage Alzheimer’s under the traditional pathway.

The Centers for Medicare & Medicaid Services (CMS) followed with expanded coverage. It propelled policy support for disease-modifying therapies, which has started to influence investment flows and pricing strategies in the U.S. Canada has also exhibited increased openness toward novel treatments. Health Canada approved Leqembi in late 2023 but with limited reimbursement guidelines compared to the U.S. This shows the country’s stringent cost-effectiveness thresholds.

Europe Neurodegenerative Diseases Drugs Market Trends

Europe’s market is characterized by rigorous regulatory standards, cost-effectiveness thresholds, and increasing public sector involvement. The European Medicines Agency (EMA) granted conditional marketing authorization to Biogen and Eisai’s Leqembi in November 2024. However, Germany and France have been slower to integrate it into national reimbursement systems due to unresolved concerns over clinical benefit and long-term economic value. The German Federal Joint Committee (G-BA) evaluated Leqembi in early 2025 and assigned it a ‘minor additional benefit’ rating. It further affected pricing negotiations and access timelines.

Europe is also seeing increasing investment in decentralized clinical trials and Real-World Data (RWD) infrastructure to better assess treatment outcomes in aging populations. The Innovative Health Initiative (IHI), launched in 2022 under Horizon Europe, has funneled over €100 Mn into neurodegenerative research. It includes projects such as NEUROCURE and the European Platform for Neurodegenerative Diseases (EPND). These aim to boost biomarker validation and harmonize data sharing across borders.

Asia Pacific Neurodegenerative Diseases Drugs Market Trends

Asia Pacific is evolving rapidly with demographic pressure, government-backed research incentives, and increasing local development. Japan remains the regional frontrunner, both in drug development and regulatory agility. In September 2023, Japan's Pharmaceuticals and Medical Devices Agency (PMDA) approved lecanemab (Leqembi) for early-stage Alzheimer’s, just months after the U.S. PMDA also included it under the National Health Insurance scheme, which was considered a swift decision to address the country's urgent focus on dementia.

China is investing in neurodegenerative drug discovery under its Healthy China 2030 initiative. Players such as Green Valley Pharmaceuticals have gained traction with GV-971, a marine algae-derived drug for Alzheimer’s. The company announced in early 2025 that it is now conducting a global Phase 3 trial across Asia Pacific, North America, and Europe. South Korea is emerging as a precision medicine hub, with biotech firms such as Peptron and Medytox developing peptide and botulinum-based therapies for neurodegenerative disorders.

global-neurodegenerative-diseases-drugs-market-outlook-by-region-2025–2032

Request Free sampleRequest Free sample

Competitive Landscape

The neurodegenerative diseases drugs market is highly fragmented with rising burden of Alzheimer's, Parkinson's, ALS, and Huntington’s disease. Large pharmaceutical firms dominate the market with late-stage pipeline assets and FDA-approved treatments. Small-scale companies are boosting candidates with unique modalities, including blood-brain barrier-penetrant biologics and small molecules that modulate lysosomal function. There is also a surging interest in gene therapies and antisense oligonucleotides, mainly for rare and genetically defined disorders. Strategic collaborations are also gaining momentum among big pharma and small biotech firms to develop next-generation drugs.

Key Industry Developments

In July 2025, Klotho Neurosciences bagged the FDA Orphan Drug Designation for KLTO-202, it unique secreted-Klotho promoter gene therapy for treating Amyotrophic Lateral Sclerosis (ALS). The designation provides key benefits, including 7 years of market exclusivity, GDUFA User Fee waivers, and tax credits for clinical trials.
In March 2025, Alpha Cognition Inc. declared the official commercial launch of ZUNVEYL. It is a new treatment for mild to moderate Alzheimer’s disease. With this launch, the company aims to deliver innovative and accessible solutions for patients and caregivers.

Companies Covered in Neurodegenerative Diseases Drugs Market

Biogen
Pfizer, Inc.
Hoffmann-La Roche Ltd.
Merck & Co., Inc.
Novartis AG
Sanofi
Teva Pharmaceutical Industries Ltd.
Orion Pharma
UCB S.A
ACADIA Pharmaceuticals Inc.
Lundbeck A/S
Mitsubishi Tanabe Pharma Corporation
Others

Frequently Asked Questions

The neurodegenerative diseases drugs market is projected to reach US$ 58.4 Bn in 2025.

High unmet demand for disease-modifying treatments and regulatory support for neurology-focused research activities are the key market drivers.

The neurodegenerative diseases drugs market is poised to witness a CAGR of 5.5% from 2025 to 2032.

The development of precision therapies and companion diagnostic co-development are the key market opportunities.

Biogen, Pfizer, Inc., and Hoffmann-La Roche Ltd. are a few key market players.

Top-Down Market Sizing	Bottom-Up Market Sizing
Universe Definition: Total global/regional market identification	Unit Economics: Average transaction values, purchase frequencies, customer lifecycle
Segmentation Filters: Geographic, demographic, and behavioral constraints	Customer Segmentation: Detailed buyer persona development and sizing
Market Share Analysis: Competitive landscape assessment and share allocation	Penetration Analysis: Market penetration rates by segment and geography
Growth Rate Application: Historical trends and forward-looking growth assumptions	Scaling Methodology: Extrapolation techniques with confidence intervals

Interested in this report?

Request customization, ask for expert consulting, access a sample report, or simply express your interest—our team will assist you with the right insights and solutions.

Request Custom VersionRequest Custom Version

Clients

Media Citation

Get In Touch

Loading page data

Please wait a moment

Executive Summary
1. Global Neurodegenerative Diseases Drugs Market Snapshot, 2025 and 2032
2. Market Opportunity Assessment, 2025 - 2032, US$ Bn
3. Key Market Trends
4. Future Market Projections
5. Premium Market Insights
6. Industry Developments and Key Market Events
7. PMR Analysis and Recommendations
Market Overview
1. Market Scope and Definition
2. Market Dynamics
  1. Drivers
  2. Restraints
  3. Opportunity
  4. Challenges
  5. Key Trends
3. Macro-economic Factors
  1. Increasing Prevalence of Neurodegenerative Diseases
  2. Government Initiatives to Improve Research Activities
4. COVID-19 Impact Analysis
5. Forecast Factors - Relevance and Impact
Value Added Insights
1. Regulatory Landscape
2. Drug Class Adoption Analysis
3. Key Deals and Mergers
4. PESTLE Analysis
5. Porter’s Five Force Analysis
Global Neurodegenerative Diseases Drugs Market Outlook
1. Key Highlights
  1. Market Size (US$ Bn) and Y-o-Y Growth
  2. Absolute $ Opportunity
2. Market Size (US$ Bn) Analysis and Forecast
  1. Historical Market Size (US$ Bn) Analysis, 2019-2024
  2. Market Size (US$ Bn) Analysis and Forecast, 2025-2032
3. Global Neurodegenerative Diseases Drugs Market Outlook: Drug Class
  1. Introduction / Key Findings
  2. Historical Market Size (US$ Bn) Analysis, By Drug Class, 2019 - 2024
  3. Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2025 - 2032
    1. Immunomodulator
    2. Interferons
    3. Decarboxylase Inhibitors
    4. Dopamine Agonists
    5. Others
  4. Market Attractiveness Analysis: Drug Class
4. Global Neurodegenerative Diseases Drugs Market Outlook: Disease Indication
  1. Introduction / Key Findings
  2. Historical Market Size (US$ Bn) Analysis, By Disease Indication, 2019 - 2024
  3. Market Size (US$ Bn) Analysis and Forecast, By Disease Indication, 2025 - 2032
    1. Multiple Sclerosis
    2. Parkinson’s Disease
    3. Alzheimer's Disease
    4. Spinal Muscular Atrophy (SMA)
    5. Others
  4. Market Attractiveness Analysis: Disease Indication
5. Global Neurodegenerative Diseases Drugs Market Outlook: Route of Administration
  1. Introduction / Key Findings
  2. Historical Market Size (US$ Bn) Analysis, By Route of Administration, 2019 - 2024
  3. Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2025 - 2032
    1. Oral
    2. Injection
    3. Transdermal
  4. Market Attractiveness Analysis: Route of Administration
6. Global Neurodegenerative Diseases Drugs Market Outlook: End Use
  1. Introduction / Key Findings
  2. Historical Market Size (US$ Bn) Analysis, By End Use, 2019 - 2024
  3. Market Size (US$ Bn) Analysis and Forecast, By End Use, 2025 - 2032
    1. Hospital Pharmacy
    2. Retail Pharmacy
    3. Online Pharmacy
  4. Market Attractiveness Analysis: End Use
Global Neurodegenerative Diseases Drugs Market Outlook: Region
1. Key Highlights
2. Historical Market Size (US$ Bn) Analysis, By Region, 2019 - 2024
3. Market Size (US$ Bn) Analysis and Forecast, By Region, 2025 - 2032
  1. North America
  2. Europe
  3. East Asia
  4. South Asia and Oceania
  5. Latin America
  6. Middle East & Africa
4. Market Attractiveness Analysis: Region
North America Neurodegenerative Diseases Drugs Market Outlook
1. Key Highlights
2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
  1. By Country
  2. By Drug Class
  3. By Disease Indication
  4. By Route of Administration
  5. By End Use
3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
  1. U.S.
  2. Canada
4. Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2025 - 2032
  1. Immunomodulator
  2. Interferons
  3. Decarboxylase Inhibitors
  4. Dopamine Agonists
  5. Others
5. Market Size (US$ Bn) Analysis and Forecast, By Disease Indication, 2025 - 2032
  1. Multiple Sclerosis
  2. Parkinson’s Disease
  3. Alzheimer's Disease
  4. Spinal Muscular Atrophy (SMA)
  5. Others
6. Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2025 - 2032
  1. Oral
  2. Injection
  3. Transdermal
7. Market Size (US$ Bn) Analysis and Forecast, By End Use, 2025 - 2032
  1. Hospital Pharmacy
  2. Retail Pharmacy
  3. Online Pharmacy
8. Market Attractiveness Analysis
Europe Neurodegenerative Diseases Drugs Market Outlook
1. Key Highlights
2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
  1. By Country
  2. By Drug Class
  3. By Disease Indication
  4. By Route of Administration
  5. By End Use
3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
  1. Germany
  2. France
  3. U.K.
  4. Italy
  5. Spain
  6. Russia
  7. Türkiye
  8. Rest of Europe
4. Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2025 - 2032
  1. Immunomodulator
  2. Interferons
  3. Decarboxylase Inhibitors
  4. Dopamine Agonists
  5. Others
5. Market Size (US$ Bn) Analysis and Forecast, By Disease Indication, 2025 - 2032
  1. Multiple Sclerosis
  2. Parkinson’s Disease
  3. Alzheimer's Disease
  4. Spinal Muscular Atrophy (SMA)
  5. Others
6. Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2025 - 2032
  1. Oral
  2. Injection
  3. Transdermal
7. Market Size (US$ Bn) Analysis and Forecast, By End Use, 2025 - 2032
  1. Hospital Pharmacy
  2. Retail Pharmacy
  3. Online Pharmacy
8. Market Attractiveness Analysis
East Asia Neurodegenerative Diseases Drugs Market Outlook
1. Key Highlights
2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
  1. By Country
  2. By Drug Class
  3. By Disease Indication
  4. By Route of Administration
  5. By End Use
3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
  1. China
  2. Japan
  3. South Korea
4. Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2025 - 2032
  1. Immunomodulator
  2. Interferons
  3. Decarboxylase Inhibitors
  4. Dopamine Agonists
  5. Others
5. Market Size (US$ Bn) Analysis and Forecast, By Disease Indication, 2025 - 2032
  1. Multiple Sclerosis
  2. Parkinson’s Disease
  3. Alzheimer's Disease
  4. Spinal Muscular Atrophy (SMA)
  5. Others
6. Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2025 - 2032
  1. Oral
  2. Injection
  3. Transdermal
7. Market Size (US$ Bn) Analysis and Forecast, By End Use, 2025 - 2032
  1. Hospital Pharmacy
  2. Retail Pharmacy
  3. Online Pharmacy
8. Market Attractiveness Analysis
South Asia & Oceania Neurodegenerative Diseases Drugs Market Outlook
1. Key Highlights
2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
  1. By Country
  2. By Drug Class
  3. By Disease Indication
  4. By Route of Administration
  5. By End Use
3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
  1. India
  2. Southeast Asia
  3. ANZ
  4. Rest of South Asia & Oceania
4. Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2025 - 2032
  1. Immunomodulator
  2. Interferons
  3. Decarboxylase Inhibitors
  4. Dopamine Agonists
  5. Others
5. Market Size (US$ Bn) Analysis and Forecast, By Disease Indication, 2025 - 2032
  1. Multiple Sclerosis
  2. Parkinson’s Disease
  3. Alzheimer's Disease
  4. Spinal Muscular Atrophy (SMA)
  5. Others
6. Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2025 - 2032
  1. Oral
  2. Injection
  3. Transdermal
7. Market Size (US$ Bn) Analysis and Forecast, By End Use, 2025 - 2032
  1. Hospital Pharmacy
  2. Retail Pharmacy
  3. Online Pharmacy
8. Market Attractiveness Analysis
Latin America Neurodegenerative Diseases Drugs Market Outlook
1. Key Highlights
2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
  1. By Country
  2. By Drug Class
  3. By Disease Indication
  4. By Route of Administration
  5. By End Use
3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
  1. Brazil
  2. Mexico
  3. Rest of Latin America
4. Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2025 - 2032
  1. Immunomodulator
  2. Interferons
  3. Decarboxylase Inhibitors
  4. Dopamine Agonists
  5. Others
5. Market Size (US$ Bn) Analysis and Forecast, By Disease Indication, 2025 - 2032
  1. Multiple Sclerosis
  2. Parkinson’s Disease
  3. Alzheimer's Disease
  4. Spinal Muscular Atrophy (SMA)
  5. Others
6. Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2025 - 2032
  1. Oral
  2. Injection
  3. Transdermal
7. Market Size (US$ Bn) Analysis and Forecast, By End Use, 2025 - 2032
  1. Hospital Pharmacy
  2. Retail Pharmacy
  3. Online Pharmacy
8. Market Attractiveness Analysis
Middle East & Africa Neurodegenerative Diseases Drugs Market Outlook
1. Key Highlights
2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
  1. By Country
  2. By Drug Class
  3. By End Use
3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
  1. GCC Countries
  2. Egypt
  3. South Africa
  4. Northern Africa
  5. Rest of Middle East & Africa
4. Market Size (US$ Bn) Analysis and Forecast, By Drug Class, 2025 - 2032
  1. Immunomodulator
  2. Interferons
  3. Decarboxylase Inhibitors
  4. Dopamine Agonists
  5. Others
5. Market Size (US$ Bn) Analysis and Forecast, By Disease Indication, 2025 - 2032
  1. Multiple Sclerosis
  2. Parkinson’s Disease
  3. Alzheimer's Disease
  4. Spinal Muscular Atrophy (SMA)
  5. Others
6. Market Size (US$ Bn) Analysis and Forecast, By Route of Administration, 2025 - 2032
  1. Oral
  2. Injection
  3. Transdermal
7. Market Size (US$ Bn) Analysis and Forecast, By End Use, 2025 - 2032
  1. Hospital Pharmacy
  2. Retail Pharmacy
  3. Online Pharmacy
8. Market Attractiveness Analysis
Competition Landscape
1. Market Share Analysis, 2025
2. Market Structure
  1. Competition Intensity Mapping By Market
  2. Competition Dashboard
3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  1. Biogen
    1. Overview
    2. Segments and Drug Class
    3. Key Financials
    4. Market Developments
    5. Market Strategy
  2. Pfizer, Inc.
  3. Hoffmann-La Roche Ltd.
  4. Merck & Co., Inc.
  5. Novartis AG
  6. Sanofi
  7. Teva Pharmaceutical Industries Ltd.
  8. Orion Pharma
  9. UCB S.A
  10. ACADIA Pharmaceuticals Inc.
  11. Lundbeck A/S
  12. Mitsubishi Tanabe Pharma Corporation
  13. Others
Appendix
1. Research Methodology
2. Research Assumptions
3. Acronyms and Abbreviations

Report Attribute	Details
Historical Data/Actuals	2019 - 2024
Forecast Period	2025 - 2032
Market Analysis	Value: US$ Bn/Mn, Volume: As Applicable
Geographical Coverage	North America Europe East Asia South Asia and Oceania Latin America Middle East and Africa
Segmental Coverage	Drug Class Disease Indication Route of Administration End-use Region
Competitive Analysis	Biogen Pfizer, Inc. Hoffmann-La Roche Ltd. Merck & Co., Inc. Novartis AG Sanofi Teva Pharmaceutical Industries Ltd. Orion Pharma UCB S.A ACADIA Pharmaceuticals Inc. Lundbeck A/S Mitsubishi Tanabe Pharma Corporation Others
Report Highlights	Market Forecast and Trends Competitive Intelligence and Share Analysis Growth Factors and Challenges Strategic Growth Initiatives Pricing Analysis Future Opportunities and Revenue Pockets Market Analysis Tools
Customization and Pricing	Available upon request

Report Attribute	Details
Historical Data/Actuals	2019 - 2024
Forecast Period	2025 - 2032
Market Analysis	Value: US$ Bn/Mn, Volume: As Applicable
Geographical Coverage	North America Europe East Asia South Asia and Oceania Latin America Middle East and Africa
Segmental Coverage	Drug Class Disease Indication Route of Administration End-use Region
Competitive Analysis	Biogen Pfizer, Inc. Hoffmann-La Roche Ltd. Merck & Co., Inc. Novartis AG Sanofi Teva Pharmaceutical Industries Ltd. Orion Pharma UCB S.A ACADIA Pharmaceuticals Inc. Lundbeck A/S Mitsubishi Tanabe Pharma Corporation Others
Report Highlights	Market Forecast and Trends Competitive Intelligence and Share Analysis Growth Factors and Challenges Strategic Growth Initiatives Pricing Analysis Future Opportunities and Revenue Pockets Market Analysis Tools
Customization and Pricing	Available upon request

Neurodegenerative Diseases Drugs Market Size, Share, Trends, Growth, and Forecasts for 2025 - 2032

Neurodegenerative Diseases Drugs Market by Drug Class (Immunomodulator, Interferons), by Disease Indication (Multiple Sclerosis, Parkinson’s Disease), by Route of Administration (Oral, Injection), by End-use, and Regional Analysis for 2025 - 2032